natgillin/translations-raw huggingface dataset:
Mixtard 30 InnoLet 100 international units/ml suspension for injection in pre-filled pen.
Mixtard 30 InnoLet 100 mednarodnih enot/ml suspenzija za injiciranje v napolnjenem injekcijskem peresniku
Mixtard 30 InnoLet, Mixtard 40 and 50 Penfill:
Mixtard 30 InnoLet, Mixtard 40 in 50 Penfill:
Mixtard 30 Penfill 100 international units/ml suspension for injection in cartridge human insulin
Mixtard 30 Penfill 100 mednarodnih enot/ml suspenzija za injiciranje v injekcijskem vložku humani insulin
Mixtard 30 Penfill 100 international units/ml suspension for injection in cartridge.
Mixtard 30 Penfill 100 mednarodnih enot/ml suspenzija za injiciranje v injekcijskem vložku
Mixtard 30 vial, Penfill and FlexPen:
Mixtard 30 viala, Penfill in FlexPen:
Mixtard 30: soluble insulin 30% and isophane insulin 70%;
Mixtard 30: 30 % topnega insulina in 70 % insulina izofan;
Mixtard 40 Penfill 100 international units/ml suspension for injection in cartridge human insulin
Mixtard 40 Penfill 100 mednarodnih enot/ml suspenzija za injiciranje v injekcijskem vložku humani insulin
Mixtard 40 Penfill 100 international units/ml suspension for injection in cartridge.
Mixtard 40 Penfill 100 mednarodnih enot/ml suspenzija za injiciranje v injekcijskem vložku
Mixtard 40: soluble insulin 40% and isophane insulin 60%;
Mixtard 40: 40 % topnega insulina in 60 % insulina izofan;
Mixtard 50 Penfill 100 international units/ml suspension for injection in cartridge human insulin
Mixtard 50 Penfill 100 mednarodnih enot/ml suspenzija za injiciranje v injekcijskem vložku humani insulin
Mixtard 50 Penfill 100 international units/ml suspension for injection in cartridge.
Mixtard 50 Penfill 100 mednarodnih enot/ml suspenzija za injiciranje v injekcijskem vložku
Mixtard 50: soluble insulin 50% and isophane insulin 50%.
Mixtard 50: 50 % topnega insulina in 50 % insulina izofan.
Mixtard can be used in children and adolescents.
Zdravilo Mixtard se lahko uporablja pri otrocih in mladostnikih.
Mixtard contains sodium
Zdravilo Mixtard vsebuje natrij
Mixtard FlexPen is a pre-filled pen designed to be used with NovoFine or NovoTwist disposable needles up to a length of 8 mm.
Mixtard FlexPen je napolnjen injekcijski peresnik, namenjen za uporabo z iglami NovoFine ali NovoTwist za enkratno uporabo, dolžine do 8 mm.
Mixtard FlexPen is accompanied by a package leaflet with detailed instructions for use to be followed.
Zdravilu Mixtard FlexPen je priloženo navodilo za uporabo s podrobnimi napotki, ki jih je treba natančno upoštevati.
Mixtard InnoLet is a pre-filled pen designed to be used with NovoFine or NovoTwist disposable needles up to a length of 8 mm.
Mixtard InnoLet je napolnjen injekcijski peresnik, namenjen za uporabo z iglami NovoFine ali NovoTwist za enkratno uporabo, dolžine do 8 mm.
Mixtard InnoLet is accompanied by a package leaflet with detailed instructions for use to be followed.
Zdravilu Mixtard InnoLet je priloženo navodilo za uporabo s podrobnimi napotki, ki jih je treba natančno upoštevati.
Mixtard vial is accompanied by a package leaflet with detailed instructions for use to be followed.
Viali z zdravilom Mixtard je priloženo navodilo za uporabo s podrobnimi napotki, ki jih je treba natančno upoštevati.
Mixtard vials are for use with insulin syringes with the corresponding unit scale.
Viale zdravila Mixtard so namenjene uporabi z insulinskimi brizgami, ki imajo ustrezno odmerno skalo.
Mixtard with alcohol
Zdravilo Mixtard skupaj z alkoholom
ml (Fill 2.36 ml)
ml (polnitev 2,36 ml)
mL cartridge (type I glass, with a bromobutyl rubber plunger stopper and an aluminium crimp cap with bromobutyl rubber) preassembled in a prefilled pen.
ml vložek (steklo tip I z bromobutilnim batnim zamaškom in aluminijasto zaporko z bromobutilno gumo), sestavljeno v napolnjenem injekcijskem peresniku.
ml clear glass Type I vial with a bromobutyl rubber stopper and aluminium seal and a plastic flip-off cap containing 1 ml of concentrate for solution for infusion.
6 ml viala iz prozornega stekla tipa I z bromobutilno gumijasto zaporko in aluminijastim pečatom in plastično dvižno zaporko z 1 ml koncentrata za raztopino za infundiranje.
ml clear, colourless Type-I glass vial, closed with flurotec rubber stopper and a blue flip-off aluminium over seal containing 4 ml of concentrate.
6 ml viala iz prozornega, brezbarvnega stekla tipa I, zaprta z gumijastim zamaškom in modro snemno (flip-off) aluminijasto prekrivno zaporko, ki vsebuje 4 ml koncentrata.
ml clear, colourless Type-I glass vial, closed with flurotec rubber stopper and a green flip-off aluminium over seal containing 1 ml of concentrate.
6 ml viala iz prozornega, brezbarvnega stekla tipa I, zaprta z gumijastim zamaškom in zeleno snemno (flip-off) aluminijasto prekrivno zaporko, ki vsebuje 1 ml koncentrata.
ml clear, colourless Type-I glass vial, closed with flurotec rubber stopper and a red flip-off aluminium over seal containing 6 ml of concentrate.
6 ml viala iz prozornega, brezbarvnega stekla tipa I, zaprta z gumijastim zamaškom in rdečo snemno (flip-off) aluminijasto prekrivno zaporko, ki vsebuje 6 ml koncentrata.
ml concentrate in plastic vial made of clear, colourless cycloolefine copolymer with Type I bromobutyl rubber stopper and sealed with aluminium polypropylene flip off seal.
5 ml koncentrat v plastični viali, izdelani iz prozornega, brezbarvnega cikloolefinskega kopolimera tipa I, z zamaškom iz bromobutilne gume, prevlečena z aluminijasto polipropilensko odtržno zaporko.
ml contains 100 U (approximately 0.58 mg) of laronidase.
1 ml vsebuje 100 e (približno 0,58 mg) laronidaze.
ml contains 100 units (3.64 mg) insulin glargine
ml vsebuje 100 enot (3,64 mg) insulina glargin.
ml contains:
ml vsebuje:
ml of solution (corresponding to 18 MIU) in a vial (type I glass), with a stopper (halobutyl rubber) in a flip- off seal (aluminium) with a bonnet (polypropylene).
3 ml raztopine (kar ustreza 18 milijonom i.e.) v viali (iz stekla tipa I), z zamaškom (iz halobutilne gume) in zaporko s ploščico (iz aluminija) s pokrovčkom (iz polipropilena).
mL of solution (corresponding to 18 MIU) is contained in a multidose vial (type I glass) with a stopper (halobutyl rubber) in a flip-off seal (aluminium) with a bonnet (polypropylene).
ml raztopine (kar ustreza 18 milijonom i.e.) je v viali z več odmerki (iz stekla tipa I), z zamaškom (iz halobutilne gume) in zaporko s ploščico (iz aluminija) s pokrovčkom (iz polipropilena).
ml of solution contains 0.9 mg bromfenac (as sodium sesquihydrate).
1 ml raztopine vsebuje 0,9 mg bromfenaka (v obliki natrijevega seskvihidrata).
ml of solution contains emedastine 0.5 mg (as difumarate).
ml raztopine vsebuje 0,5 mg emedastina (v obliki difumarata).
ml of solution in a 3 ml pre-filled syringe (type I glass) with plunger stopper (bromobutyl coated with fluorocarbon polymer).
ml raztopine v 3 ml napolnjeni injekcijski brizgi (steklo tipa I) z batno zaporko (bromobutil, prevlečen s fluoroogljikovim polimerom).
ml of solution in a 5 ml vial (type I glass) closed with a stopper (bromobutyl/isoprene polymer) and a seal (lacquered plastic).
ml raztopine v 5-ml viali (steklo tipa I), ki je zaprta z zamaškom (bromobutil/izoprenski polimer) in zapečatena (lakirana plastika).
ml oral solution 150 ml oral solution 480 ml oral solution
ml peroralne raztopine 150 ml peroralne raztopine 480 ml peroralne raztopine
ml product/day = Total estimated body weight (kg) of chicken to be treated x 0.005 ml Examples:
ml zdravila/dan = celotna ocenjena telesna masa (kg) piščancev, ki jih boste zdravili, x 0,005 ml Primeri:
ml product/day = Total estimated body weight (kg) of pigs to be treated x 0.0125 ml Examples:
ml zdravila/dan = celotna ocenjena telesna masa (kg) prašičev, ki jih boste zdravili, x 0,0125 ml Primeri:
ml round opaque low density polyethylene bottles with a dispensing plug and white polypropylene screw cap (DROP-TAINER) containing 5 ml suspension.
ml okrogli neprozorni kapalni vsebniki iz polietilena nizke gostote s kapalnim delom in belo polipropilensko navojno zaporko (DROP-TAINER), ki vsebujejo po 5 ml suspenzije.
ml solution contains 100 units insulin detemir (equivalent to 14.2 mg).
napolnjen injekcijski peresnik s 3 ml vsebuje 300 enot.
ml solution in a cartridge (colourless glass) with a plunger (elastomeric bromobutyl rubber) and a flanged cap (aluminium) with a stopper (elastomeric bromobutyl rubber).
ml raztopine v vložku (iz brezbarvnega stekla) z batom (iz elastomerne bromobutilne gume) in s prirobljeno zaporko (iz aluminija) z zamaškom (iz elastomerne bromobutilne gume).
ml solution in a cartridge (type 1 colourless glass) with a plunger (bromobutyl rubber (type 1)) and a flanged cap (aluminium) with a stopper (bromobutyl or laminate of polyisoprene and bromobutyl rubber (type 1)).
ml raztopina v vložku (iz brezbarvnega stekla tipa 1) z batom (iz brombutilne gume (tipa 1)) in prirobljeno zaporko ( iz aluminija) z zamaškom (iz brombutilne ali laminata poliizoprenske in brombutilne gume (tipa 1)).
ml solution in a cartridge (type 1 colourless glass) with a plunger (bromobutyl rubber (type 1)) and a flanged cap (aluminium) with a stopper (bromobutyl or laminate of polyisoprene and bromobutyl rubber (type 1)).
ml raztopina v vložku (iz brezbarvnega stekla tipa 1), z batom (iz brombutilne gume (tipa 1)) ter s prirobljeno zaporko (iz aluminija) z zamaškom (iz brombutilne ali laminata poliizoprenske in brombutilne gume (tipa 1)).
ml solution in a cartridge (type 1 colourless glass) with a plunger (bromobutyl rubber (type 1)) and a flanged cap (aluminium) with a stopper (bromobutyl or laminate of polyisoprene and bromobutyl rubber (type 1)).
ml suspenzija v vložku (iz brezbarvnega stekla tipa 1) z batom (iz brombutilne gume (tipa 1)) in s prirobljeno zaporko (iz aluminija) z zamaškom (iz brombutilne ali laminata poliizoprenske in brombutilne gume (tipa 1)).
mL solution in a cartridge (type 1 colourless glass) with a plunger (chlorobutyl rubber) and a disc seal (laminate of polyisoprene and bromobutyl rubber) with aluminium seal.
3 ml raztopine v vložku (iz brezbarvnega stekla tipa 1) z batom (iz klorobutilne gume) in zaporno ploščico (iz poliizoprenskega laminata in brombutilne gume) z aluminijasto zaporko.
mL solution in a cartridge (type 1 glass) with a plunger (halobutyl) and a stopper (halobutyl/polyisoprene) contained in a pre-filled multidose disposable pen made of polypropylene, polycarbonate and acrylonitrile butadiene styrene.
ml raztopine v injekcijskem vložku (steklo tipa 1) z batom (halobutil) in zamaškom (halobutil/poliizopren) v večodmernem napolnjenem injekcijskem peresniku iz polipropilena, polikarbonata in akrilonitril butadien stirena, ki se ga zavrže.
ml solution in a cartridge (type I colourless glass) with a plunger (elastomeric bromobutyl rubber) and a flanged cap (aluminium) with a stopper (elastomeric bromobutyl rubber).
ml raztopine v vložku (iz brezbarvnega stekla tipa 1) z batom (iz elastomerne bromobutilne gume) in s prirobljeno zaporko (iz aluminija) z zamaškom (iz elastomerne bromobutilne gume).
ml solution in a single use Type 1 glass vial with (butyl) rubber stopper and aluminium over-seal.
ml raztopine v stekleni viali (tipa 1) za enkratno uporabo z (butilnim) gumijastim zamaškom in aluminijasto vrhnjo zaporko.
ml suspension contains 1 g mycophenolate mofetil when reconstituted.
ml pripravljene suspenzije vsebuje 1 g mofetilmikofenolata.
ml suspension in a cartridge (type 1 colourless glass) with a plunger (bromobutyl rubber (type 1)) and a flanged cap (aluminium) with a stopper (bromobutyl or laminate of polyisoprene and bromobutyl rubber (type 1)).
ml suspenzija v vložku (iz brezbarvnega stekla tipa 1) z batom (iz brombutilne gume (tipa 1)) in prirobljeno zaporko (iz aluminija) z zamaškom (iz brombutilne ali laminata poliizoprenske in brombutilne gume (tipa 1)).
ml suspension in a cartridge (type 1 colourless glass) with a plunger (bromobutyl rubber (type 1)) and a flanged cap (aluminium) with a stopper (bromobutyl or laminate of polyisoprene and bromobutyl rubber (type 1)).
ml suspenzija v vložku (iz brezbarvnega stekla tipa 1) z batom (iz brombutilne gume (tipa 1)) in prirobljeno zaporko (iz aluminjija) z zamaškom (iz brombutilne ali laminata poliizoprenske in brombutilne gume (tipa 1)).
ml suspension in a cartridge (type 1 colourless glass) with a plunger (bromobutyl rubber (type 1)) and a flanged cap (aluminium) with a stopper (bromobutyl or laminate of polyisoprene and bromobutyl rubber (type 1)).
ml suspenzija v vložku (iz brezbarvnega stekla tipa 1) z batom (iz brombutilne gume (tipa 1)) in s prirobljeno zaporko (iz aluminija) z zamaškom (iz brombutilne ali laminata poliizoprenske in brombutilne gume (tipa 1)).
ml suspension in a cartridge (type 1 colourless glass) with a plunger (bromobutyl rubber (type 1)) and a flanged cap (aluminium) with a stopper (bromobutyl or laminate of polyisoprene and bromobutyl rubber (type 1)).
ml suspenzija v vložku (iz brezbarvnega stekla tipa 1) z batom (iz brombutilne gume (tipa 1)) in s prirobljeno zaporko (iz aluminija), z zamaškom (iz brombutilne ali laminata poliizoprenske in brombutilne gume (tipa 1)).
ml suspension in a cartridge (type 1 colourless glass) with a plunger (bromobutyl rubber (type 1)) and a flanged cap (aluminium) with a stopper (bromobutyl or laminate of polyisoprene and bromobutyl rubber (type 1)).
ml suspenzija v vložku (iz brezbarvnega stekla tipa 1) z batom i(z brombutilne gume (tipa 1)) in prirobljeno zaporko (iz aluminija) z zamaškom (iz brombutilne ali laminata poliizoprenske in brombutilne gume (tipa 1)).
ml suspension in a cartridge (type 1 colourless glass) with a plunger (bromobutyl rubber (type 1)) and a flanged cap (aluminium) with a stopper (bromobutyl or laminate of polyisoprene and bromobutyl rubber (type 1)).
ml suspenzija v vložku (iz brezbarvnega stekla tipa 1), batom (iz brombutilne gume (tipa 1)) ter prirobljeno zaporko (iz aluminija) z zamaškom (iz brombutilne ali laminata poliizoprenske in brombutilne gume (tipa 1)).
ml suspension in a cartridge (type 1 colourless glass) with a plunger (bromobutyl rubber (type 1)) and a flanged cap (aluminium) with a stopper (bromobutyl or laminate of polyisoprene and bromobutyl rubber (type 1)).
ml suspenzija v vložku (iz brezbarvnega stekla tipa 1), z batom (iz brombutilne gume (tip 1)) ter prirobljeno zaporko (iz aluminija) z zamaškom (iz brombutilne ali laminata poliizoprenske in brombutilne gume (tip 1)).
ml suspension in a cartridge (type 1 colourless glass) with a plunger (bromobutyl rubber (type 1)) and a flanged cap (aluminium) with a stopper (bromobutyl or laminate of polyisoprene and bromobutyl rubber (type 1)).
ml suspenzija v vložku (iz brezbarvnega stekla tipa 1), z batom (iz brombutilne gume (tipa 1)) ter s prirobljeno zaporko (iz aluminija) z zamaškom (iz brombutilne ali laminata poliizoprenske in brombutilne gume (tipa 1)).
ml suspension in a cartridge (type 1 colourless glass) with a plunger (bromobutyl rubber (type 1)) and a flanged cap (aluminium) with a stopper (bromobutyl or laminate of polyisoprene and bromobutyl rubber (type 1)).
ml suspenzija v vložku (iz brezbarvnega stekla tipa 1), z batom iz brombutilne gume (tipa 1) ter s prirobljeno aluminijsko zaporko z zamaškom iz brombutilne ali laminata poliizoprenske in brombutilne gume (tipa 1).
ml type I glass vial, with teflon-coated, butyl rubber stopper and flip-off aluminium over seal, containing 2 ml of solution.
ml viala iz stekla tipa I z zamaškom iz butilne gume, obloženim s teflonom, in dvižno aluminijasto vrhnjo zaporko prek tesnila, ki vsebuje 2 ml raztopine.
ml vial (type 1 clear glass) with a stopper (chlorobutyl rubber), seal (aluminium) and a flip-off cap (polypropylene).
5 ml viala (iz prozornega stekla tipa 1) z zamaškom (iz klorobutilne gume), zaporo (iz aluminija) in snemno zaporko (iz polipropilena).
ml/hour
ml/uro
ML18147: Avastin 5.0 mg/kg of body weight every 2 weeks or Avastin 7.5 mg/kg of body weight every 3 weeks in combination with fluoropyrimidine/irinotecan or fluoropyrimidine/oxaliplatin in patients with disease progression following first-line treatment with bevacizumab.
ML18147: zdravilo Avastin 5,0 mg/kg telesne mase enkrat na 2 tedna ali zdravilo Avastin 7,5 mg/kg telesne mase vsake 3 tedne v kombinaciji s fluoropirimidinom/irinotekanom ali fluoropiridinom/oksaliplatinom pri bolnikih, pri katerih je bolezen po prvi liniji zdravljenja z zdravilom Avastin napredovala.
MLSB resistance may be constitutive or inducible.
rezistenca je lahko sestavna ali pa inducirana.
mlsuspension in a cartridge (type 1 colourless glass) with a plunger (bromobutyl rubber (type 1)) and a flanged cap (aluminium) with a stopper (bromobutyl or laminate of polyisoprene and bromobutyl rubber (type 1)).
ml suspenzija v vložku (iz brezbarvnega stekla tipa 1), z batom (iz brombutilne gume (tipa 1)) ter s prirobljeno zaporko (iz aluminija) z zamaškom (iz brombutilne ali laminata poliizoprenske in brombutilne gume (tipa 1)).
MM/YYYY
LLLL
MMF: monitoring for MPA- related toxicities is advised.
MMF: priporočljivo je spremljanje toksičnih učinkov, povezanih z MPA.
MMR at 12 months
glavni molekularni odziv po 12 mesecih
MMR at 24 months
37,5 (31,8; 43,4)
MMR at 36 months2
43,8 (38,0; 49,8)
MMR at 48 months3
41,7 (35,9; 47,7)
MMR at 60 months4
37,5 (31,8; 43,4)
MMR at 72 months5
43,8 (38,0; 49,8)
MMR rates by specific timepoint are displayed graphically in Figure 2.
Deleži MMR po specifičnih časovnih točkah so grafično prikazani na sliki 2.
MMRat 12 months
glavni molekularni odziv po 12 mesecih
MMRd, % (95% CI)
MMRd, % (95 % IZ)
mMU§/mL
mME§/ml
MN
dan
MN = Multiples of Normal, CI = confidence interval
MN = večkratnik normalne vrednosti, IZ = interval zaupanja
MN = Multiples of Normal, CI = confidence interval a At baseline, mean spleen volumes were 12.5 and 13.9 MN in the placebo and Cerdelga groups, respectively, and mean liver volumes were 1.4 MN for both groups.
MN = Multiples of Normal (večkratnik normalne vrednosti), IZ = interval zaupanja a V izhodišču sta bili povprečni prostornini vranice 12,5 MN v skupini s placebom in 13,9 MN v skupini z zdravilom Cerdelga, povprečni prostornini jeter pa sta v obeh skupinah znašali 1,4 MN.
MN assay
52,6
MN assay
Test mikronevtralizacije
MN Assay All subjects Seronegative subjects at baseline (< 1:10)
Test MN Vsi preiskovanci Seronegativni preiskovanci v izhodišču (<1:10)
MN results against a A/Vietnam/1194/2004 indicate a seroprotection rate of 99% (95%CI: 94-100), a seroconversion rate ranging from 97% (95%CI: 91-99) to 99% (95%CI: 96-100) and a GMR ranging from 29 (95%CI: 25-35) to 50 (95%CI: 44-58).
Rezultati MN za sev A/Vietnam/1194/2004 kaţejo na stopnjo serozaščite 99 % (95-odstotni IZ: 94– 100), stopnjo serokonverzije v razponu od 97 % (95-odstotni IZ: 91-99) do 99% (95-odstotni IZ: 96
MN results against A/Vietnam/1194/2004 indicate a seroprotection and seroconversion rate ranging from 67% (60-74) to 85% (78-90) and 65% (58-72) to 83% (77-89), respectively.
Rezultati MN za A/Vietnam/1194/2004 kaţejo na stopnjo serozaščite v razponu od 67 % (60–74) do 85 % (78–90) in stopnjo serokonverzije v razponu od 65 % (58–72) do 83 % (77–89).
MN results against A/Vietnam/1194/2004 indicate a seroprotection and seroconversion rate ranging from of 57% (50-64) to 79% (68-87) and 55% (48-62) to 58% (47-69) respectively.
Rezultati MN za A/Vietnam/1194/2004 kaţejo na stopnjo serozaščite v razponu od 57 % (50–64) do 79 % (68–87) in stopnjo serokonverzije v razponu od 55 % (48–62) do 58 % (47–69).
MN results against A/Vietnam/1194/2004 indicate a seroprotection and seroconversion rate ranging from of 57% (50-64) to 79% (68-87) and 55% (48-62) to 58% (47-69) respectively.
Rezultati MN za A/Vietnam/1194/2004 kažejo na stopnjo serozaščite v razponu od 57 % (50–64) do 79 % (68–87) in stopnjo serokonverzije v razponu od 55 % (48–62) do 58 % (47–69).
MN results for A/H5N1/Indonesia/5/05 revealed a seroprotection rate of 38% (31-45) in adults (18-60 years) and 14% (8-20) in elderly (>60 years); a seroconversion rate of 58% (50-65) in adults and 30% (23-38) in elderly and finally a GMR of 4.67 (3.95-5.56) in adults and 2.19 (1.86-2.58) in elderly.
Výsledky MN pre kmeň A/H5N1/Indonesia/5/05 preukázali mieru séroprotekcie v rozsahu 38 % (31-45) u dospelých (18-60 rokov) a 14 % (8-20) u starších osôb (>60 rokov); mieru sérokonverzie v rozsahu 58 % (50-65) u dospelých a 30 % (23-38) u starších osôb a napokon hodnotu GMR
MN results for the clinical studies in the Table above revealed a seroprotection rate against A/turkey/Turkey/05 ranging from 11% (3-25) (study V87P1) to 30% (24-37) (study V87P13) and seroconversion rate of 25% (19-31) for study V87P13.
Rezultati MN za tri klinične študije v zgornji preglednici kažejo stopnjo serozaščite proti sevu A/turkey/Turkey/05 v razponu od 11 % (3–25) (študija V87P1) do 30 % (24–37) (študija V87P13) in stopnjo serokonverzije 25 % (19–31) za študijo V87P13.
MN results for the clinical studies in the Table above revealed a seroprotection rate against A/turkey/Turkey/05 ranging from 11% (3-25) (study V87P1) to 30% (24-37) (study V87P13) and seroconversion rate of 25% (19-31) for study V87P13.
Rezultati MN za tri klinične študije v zgornji preglednici kažejo stopnjo serozaščite proti sevu A/turkey/Turkey/05 v razponu od 11% (3–25) (študija V87P1) do 30% (24–37) (študija V87P13) in stopnjo serokonverzije 25% (19–31) za študijo V87P13.
MN results for the clinical studies in the Table above revealed a seroprotection rate against A/turkey/Turkey/05 ranging from 11% (3-25) (study V87P1) to 30% (24-37) (study V87P13) and seroconversion rate of 25% (19-31) for study V87P13.
Rezultati MN za tri klinične študije v zgornji preglednici kažejo stopnjo serozaščite proti sevu A/turkey/Turkey/05 v razponu od 11% (3–25) (študija V87P1) do 30% (24–37) (študija V87P13) in stopnjo serokonverzije v 25% (19–31) za študijo V87P13.
MN results for the clinical studies in the Table above revealed a seroprotection rate against A/turkey/Turkey/05 ranging from 27% (17-39) (V87P1) to 39% (32-46) (V87P13) and seroconversion rate of 36% (29-43) for study V87P13.
Rezultati MN za tri klinične študije v zgornji preglednici kažejo stopnjo serozaščite proti sevu A/turkey/Turkey/05 v razponu od 27 % (17–39) (V87P1) do 39 % (32–46) (V87P13) in stopnjo serokonverzije 36 % (29–43) za študijo V87P13.
MN results for the clinical studies in the Table above revealed a seroprotection rate against A/turkey/Turkey/05 ranging from 27% (17-39) (V87P1) to 39% (32-46) (V87P13) and seroconversion rate of 36% (29-43) for V87P13 study.
Rezultati MN za tri klinične študije v zgornji preglednici kažejo stopnjo serozaščite proti sevu A/turkey/Turkey/05 v razponu od 27 % (17–39) (V87P1) do 39 % (32–46) (V87P13) in stopnjo serokonverzije 36 % (29–43) za študijo V87P13.
MN results in study V87P13 yielded a GMR against A/turkey/Turkey/05 of 2.01 (1.78-2.26).
Rezultati MN v študiji V87P13 so pokazali GMR proti sevu A/turkey/Turkey/05 2,01 (1,78–2,26).
MN results in study V87P13 yielded a GMR against A/turkey/Turkey/05 of 2.77 (2.4-3.2).
Rezultati MN v študiji V87P13 so pokazali GMR proti sevu A/turkey/Turkey/05 2,77 (2,4–3,2).
MN results in V87P13 yielded a GMR against A/turkey/Turkey/05 of 2.01 (1.78-2.26).
Rezultati MN v študiji V87P13 so pokazali GMR proti sevu A/turkey/Turkey/05 2,01 (1,78–2,26).
MN results in V87P13 yielded a GMR against A/turkey/Turkey/05 of 2.77 (2.4-3.2).
Rezultati MN v V87P13 so pokazali GMR proti sevu A/turkey/Turkey/05 2,77 (2,4–3,2).
MN results in V87P13 yielded a GMR against A/turkey/Turkey/05 of 2.77 (2.4-3.2).
Rezultati MN v študiji V87P13 so pokazali GMR proti sevu A/turkey/Turkey/05 2,77 (2,4–3,2).
MN titer ≥ 20
titer MN ≥ 20
MN titre ≥ 1:40
titer MN ≥1:40
MN titre ≥ 20
titer MN ≥ 20
MN titre ≥ 20 a 21 days after 2nd dose
titer MN ≥ 20 a 21 dni po drugem odmerku
MO22224 evaluated the efficacy and safety of bevacizumab in combination with paclitaxel, topotecan, or pegylated liposomal doxorubicin in patients with platinum-resistant recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer.
Preskušanje MO22224 je ocenjevalo učinkovitost in varnost bevacizumaba v kombinaciji s paklitakselom, topotekanom ali pegiliranim liposomalnim doksorubicinom pri bolnicah s ponovitvijo epitelijskega raka jajčnikov, karcinoma jajcevodov ali primarnega peritonealnega karcinoma, rezistentnega na platino.